Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when QDEL files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsQuidelOrtho appoints Micah Young as CFO, succeeding retiring Joseph Busky
Filed June 23, 2026 · Period ending June 22, 2026 · ~1 min read
Key Changes
-
high
Micah Young appointed CFO effective July 6, 2026, succeeding Joseph Busky who announced retirement in February. Young brings extensive medtech CFO experience from Masimo (2017-2026), NuVasive, and Zimmer Holdings.
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation verify on EDGAR → -
high
New CFO's mandate focuses on improving profitability, enhancing cash generation, and creating long-term shareholder value—signaling company's strategic priorities under new financial leadership.
Exhibit 99.1 view on EDGAR → -
medium
Young receives $750,000 base salary, 100% target bonus, $500,000 sign-on bonus, and $6.5M in RSUs vesting over three years. Severance includes 2x salary plus bonus and full equity acceleration upon change-in-control termination.
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation verify on EDGAR → -
low
Busky will transition duties over six months at $340,000 annual rate, then serve as special advisor for up to 24 months at $100,000 annually to ensure continuity.
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation verify on EDGAR →
Summary
QuidelOrtho announced a planned CFO transition, with Micah Young taking over from retiring Joseph Busky effective July 6, 2026. Young brings relevant experience from his tenure as CFO of Masimo Corporation, where he led strategic transformation and capital allocation from 2017 through Masimo's acquisition by Danaher in June 2026. His prior roles at NuVasive and Zimmer Holdings add depth in medical technology finance.
The appointment signals QuidelOrtho's strategic focus on profitability improvement, cash generation, and shareholder value creation. Young's compensation package—including a substantial $6.5M equity grant vesting over three years—aligns his interests with long-term performance. Busky's six-month transition period followed by a two-year advisory role provides continuity as Young assumes the CFO responsibilities.
This is a routine leadership succession with no immediate concerns. The company disclosed Busky's retirement plans in February 2026, allowing ample time for a search that resulted in an experienced medtech CFO hire.
Section-by-Section Diff
Event · Exhibit 99.1
Added in current filing · view on EDGAR →
QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho” or the “Company”), a leading global provider of diagnostic solutions, today announced the appointment of Micah Young as Chief Financial Officer, effective July 6, 2026. Mr. Young will succeed Joseph M. Busky, who previously announced his retirement as Chief Financial Officer and will serve in an advisory role to support a smooth transition.
QuidelOrtho appointed Micah Young as Chief Financial Officer effective July 6, 2026. He succeeds Joseph M. Busky, who is retiring but will serve in an advisory role to support the transition. This is a planned leadership change with continuity measures in place.
Added in current filing · view on EDGAR →
Mr. Young most recently served as Executive Vice President and Chief Financial Officer of Masimo Corporation, a global medical technology company. He joined Masimo as CFO in 2017 and helped lead the company through a period of strategic transformation, operational improvement, disciplined capital allocation, enhanced investor engagement and significant transaction activity.
Micah Young brings extensive medical technology CFO experience, most recently serving as CFO of Masimo Corporation since 2017. During his tenure at Masimo, he led strategic transformation, operational improvement, and disciplined capital allocation. He also held senior finance roles at NuVasive and Zimmer Holdings, and began his career at Deloitte.
Added in current filing · view on EDGAR →
His leadership across business strategy, capital allocation, investor relations and financial operations will be valuable as we execute our priorities to improve profitability, enhance cash generation and create long-term shareholder value.
The CEO highlighted that the new CFO's expertise will support QuidelOrtho's priorities to improve profitability, enhance cash generation, and create long-term shareholder value. This signals the company's focus areas under the new financial leadership.
Event · Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
The Board of Directors of QuidelOrtho Corporation (the “Company”) has appointed Micah Young to serve as the Company’s Chief Financial Officer and principal financial officer, effective as of July 6, 2026 (the “Effective Date”). Mr. Young will succeed Joseph M. Busky, who previously announced his plans to retire, as disclosed in the Company’s Current Report on Form 8-K filed on February 13, 2026.
Micah Young, age 48, has been appointed CFO effective July 6, 2026, succeeding retiring CFO Joseph Busky. Young most recently served as EVP and CFO of Masimo Corporation from October 2017 until its acquisition by Danaher in June 2026, where he oversaw finance, accounting, investor relations, IT and corporate development. He previously held finance roles at NuVasive (2009-2017) and Zimmer Holdings (2002-2009), and was an auditor at Deloitte (2000-2002).
Added in current filing · verify on EDGAR →
The Company and Mr. Young have entered into an employment offer letter, dated June 22, 2026 (the “Offer Letter”), pursuant to which Mr. Young is entitled to receive (i) an annual base salary of $750,000 and (ii) an annual target cash bonus opportunity of 100% of base salary. Mr. Young will also receive a cash sign-on bonus in the amount of $500,000, and a one-time inducement sign-on grant of restricted stock units (“RSUs”) with a grant date value of $6,500,000, which is subject to vesting in equal annual installments over a three-year period.
Young's compensation includes $750,000 annual base salary, 100% target bonus, $500,000 cash sign-on bonus, and $6,500,000 in RSUs vesting over three years. He is also eligible for future equity grants with an expected 2027 value of $5,000,000 (50% time-based RSUs, 50% stock options).
Added in current filing · verify on EDGAR →
In the case of a Non-CIC Qualifying Termination, Mr. Young would generally be entitled to (i) a severance payment equal to two times the sum of his annual base salary and bonus; (ii) continued benefits coverage for up to two years; and (iii) payment of $25,000 to help defray legal, tax and accounting fees, executive outplacement services and other costs (collectively, the “Severance Benefits”). In the event of a CIC Qualifying Termination, Mr. Young would generally be entitled to the Severance Benefits, as well as full vesting and acceleration of all unvested RSUs, stock options and other equity awards.
Young's severance agreement provides 2x base salary plus bonus, two years of benefits, and $25,000 in transition costs if terminated without cause outside a change-in-control window. If terminated within two years of a change in control, he receives the same severance plus full acceleration of all unvested equity awards.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 26, 2026 · How we verify